Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04115306 · ClinicalTrials.gov registry record · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
A Phase 1 study of Metastatic Breast Cancer, sponsored by Phoenix Molecular Designs.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 11
- Study locations
NCT04115306: Recruiting Phase 1 study of Metastatic Breast Cancer, sponsored by Phoenix Molecular Designs.
NCT04115306 is a Phase 1 study of Metastatic Breast Cancer that is actively recruiting participants, run by Phoenix Molecular Designs. The registered enrollment target is 61 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (70% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04115306, a Phase 1 study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by Phoenix Molecular Designs.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
Primary Outcome
Incidence of AEs, DLTs, SAEs. Changes in laboratory, vital signs, and ECG values.
Conditions Studied
Interventions
- DRUG PMD-026
- DRUG fulvestrant
Study Locations (11)
California
- City of Hope - Duarte
- City of Hope Orange County, Lennar - Irvine
- University of California, Los Angeles (UCLA) - Los Angeles
Texas
- Oncology Consultants - Houston
- South Texas Accelerated Research Therapeutics - San Antonio
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Florida
- Moffitt Cancer Center - Tampa
Illinois
- City of Hope Chicago - Zion
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Michigan
- Profound Research - Farmington Hills
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-11-14 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
What NCT04115306 shows while recruiting
NCT04115306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which PMD-026 is the first listed.
NCT04115306 lists 11 locations in 8 states (California, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT04115306 about?
NCT04115306 is a clinical study titled "Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer". The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
What is the current status of trial NCT04115306?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2019-11-14. Estimated completion is 2026-10.
What conditions does trial NCT04115306 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT04115306?
The interventions under investigation include: PMD-026 (DRUG), fulvestrant (DRUG).
Who is sponsoring clinical trial NCT04115306?
This trial is sponsored by Phoenix Molecular Designs, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04115306 being conducted?
This trial has 11 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04115306's enrollment target sits among peer trials
61 77th of 139 higher than 62 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
- NCT05593653 · 61 participants · Phase 4
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI